INTRODUCTION {#S1}
============

Elimination of viral reservoirs is a major obstacle to the eradication of HIV ([@R11]). One such reservoir, the lymph node (LN)-resident CD4^+^ T follicular helper cell (Tfh) compartment, is a major site of ongoing viral replication ([@R5]; [@R33]; [@R46]; [@R47]). It is established that cytolytic CD8^+^ T cells are required for effective immune control of HIV and simian immunodeficiency virus (SIV) ([@R17]; [@R31]; [@R56]). However, the mechanisms of CD8^+^ T cell immunosurveillance within lymphoid tissue are not well defined. HIV/SIV-specific CD8^+^ T cells have been identified in LNs but rarely within the B cell follicles ([@R11]; [@R12], [@R13]; [@R16]; [@R44]). Recent studies also suggest that LN CD8^+^ T cells control SIV replication in extra-follicular CD4^+^ T cells, but not in follicular CD4^+^ T cells ([@R17]; [@R33]; [@R46]; [@R47], [@R48]). Accordingly, HIV-infected CD4^+^ Tfh cells are thought to evade immune surveillance largely via segregation from cytolytic CD8^+^ T cells.

Much of what is known about human CD8^+^ T cell cytolytic function, phenotype, and transcriptional regulation derives from studies of peripheral blood. In the context of HIV infection, clear associations have been demonstrated between control of HIV and HIV-specific CD8^+^ T cell cytolytic function, as measured by expression of cytolytic molecules, direct cytolytic killing capacity, and/or expression of the canonical effector function transcription factor T-bet, and control of HIV ([@R21], [@R23]; [@R39], [@R40]; [@R54]). However, it is unclear whether CD8^+^ T cell cytolytic function is manifest in HIV-infected lymphoid tissue. Intuitively, the presence of cytolytic CD8^+^ T cells in LNs, critical sites of antigen presentation and B/T cell priming, seems counterproductive for the generation and maintenance of immune responses. A number of studies in humans and mice have indeed suggested that CD8^+^ T cells in lymphoid tissue have limited cytolytic capacity ([@R4]; [@R27]; [@R53]; [@R64]; [@R66]). Nonetheless, a systematic evaluation of perforin and granzyme B expression, linked with the regulatory elements T-bet and eomesodermin, has not been reported previously for LN CD8^+^ T cells.

Here, we examined the expression of cytolytic proteins and their underlying regulatory elements in total, follicular, and HIV-specific CD8^+^ T cells in LNs. We find that CD8^+^ T cells in HIV-infected lymphoid tissue, regardless of follicular localization, display low-level, discordant, and dysregulated expression of perforin and granzyme B. These results suggest that the failure of CD8^+^ T cells to eliminate HIV-infected CD4^+^ T cells is related not only to physical segregation from infected CD4^+^ Tfh cells in lymphoid follicles but also to a generalized state of functional immune privilege against cytolytic activity in lymphoid tissue. These findings have broad implications for cure and eradication strategies designed to invoke CD8^+^ T cell-mediated clearance of HIV-infected CD4^+^ T cells.

RESULTS {#S2}
=======

Characteristics of Memory and Cytolytic CD8^+^ T Cells in HIV-Infected LNs {#S3}
--------------------------------------------------------------------------

To define the phenotypic, functional, and cytolytic properties of LN CD8^+^ T cells, we obtained LNs and peripheral blood mononuclear cells (PBMCs) from HIV^−^, chronically infected HIV^+^, and HIV^+^ individuals on antiretroviral therapy (ART; [Table 1](#T1){ref-type="table"}). We found significantly fewer memory CD8^+^ T cells within LNs compared to blood regardless of HIV infection status. However, HIV-infected individuals had expanded memory CD8^+^ T cells in blood and LNs ([Figure S1A](#SD1){ref-type="supplementary-material"}). HIV-infected LNs had increased frequencies of effector memory (CD27^−^ CD45RO^+^) CD8^+^ T cells compared to HIV^−^ subjects ([Figure 1A](#F1){ref-type="fig"}), but unlike PBMCs, LNs contained few terminally differentiated effector (CD27^−^ CD45RO^−^) CD8^+^ T cells ([Figure 1A](#F1){ref-type="fig"}).

Given the low abundance of effector CD8^+^ T cells in LNs ([Figure 1A](#F1){ref-type="fig"}), we assessed perforin and granzyme B (gzmB) expression, each linked to control of HIV disease progression ([@R23]). Compared to peripheral blood, fewer LN CD8^+^ T cells expressed perforin in HIV^−^ individuals and treated and untreated HIV^+^ individuals (p \< 0.001, [Figure 1B](#F1){ref-type="fig"}). More LN memory CD8^+^ T cells expressed perforin during chronic and ART-treated HIV infection compared to HIV^−^ individuals (p \< 0.001 and p \< 0.05, respectively). However, LN memory CD8^+^ T cells expressed less perforin per cell than PBMCs (p \< 0.001; [Figure 1B](#F1){ref-type="fig"}). Similar trends were observed for gzmB ([Figure 1C](#F1){ref-type="fig"}; data not shown). Consistent with previous reports ([@R10]; [@R22]; [@R34]), perforin and gzmB were co-expressed in blood memory CD8^+^ T cells ([Figure 1C](#F1){ref-type="fig"}) but notably dissociated in LN memory CD8^+^ T cells ([Figure 1C](#F1){ref-type="fig"}). This dissociation was somewhat mitigated in chronic HIV infection but remained evident in lymphoid tissue across all subjects. Unbiased computational t-distributed stochastic neighbor embedding (tSNE) analysis ([@R58]) of all collected parameters on memory PBMCs and LN mononuclear cells (LNMCs) in both HIV^−^ and treated and untreated HIV^+^ individuals further highlighted the dissociated nature of perforin and gzmB expression within LN memory CD8^+^ T cells and lack of the effector perforin^+^ population found in blood ([Figures 1D](#F1){ref-type="fig"} and [S1E](#SD1){ref-type="supplementary-material"}).

Cytolytic Properties of CXCR5^+^ LN Follicular CD8^+^ T Cells Are Not Associated with Control of Viremia {#S4}
--------------------------------------------------------------------------------------------------------

Recent studies suggest that follicular CXCR5^+^ CD8^+^ T cells are involved in the control of chronic viral infections ([@R20]; [@R24]; [@R32]; [@R43]; [@R48]). We therefore assessed whether the CXCR5^+^ CD8^+^ T cell population in HIV-infected LNs was present and linked to viremic control. A similar proportion (\~20%) of LN memory CD8^+^ T cells expressed CXCR5 in HIV^+^ and HIV^−^ individuals ([Figure 2A](#F2){ref-type="fig"}). We found a strong inverse correlation between the frequency of LN CXCR5^+^ CD8^+^ T cells and viral load ([Figure 2B](#F2){ref-type="fig"}), suggesting an association with control of HIV. We therefore explored whether CXCR5^+^ follicular CD8^+^ T cells expressed perforin and gzmB.

Similar to CXCR5^−^ CD8^+^ T cells, the majority of CXCR5^+^ CD8^+^ T cells in HIV^−^ LNs did not express perforin ([Figure 2C](#F2){ref-type="fig"}). The frequency of perforin-expressing cells was elevated in both CXCR5^+^ and CXCR5^−^ memory CD8^+^ T cells in HIV-infected LNs regardless of treatment status ([Figure 2C](#F2){ref-type="fig"}), with CXCR5^+^ CD8^+^ T cells being slightly more likely to express perforin. However, the overall frequency of perforin^+^ cells was still low compared to peripheral memory CD8^+^ T cells ([Figures 1B](#F1){ref-type="fig"} and [2C](#F2){ref-type="fig"}), and the low amount of perforin on a per-cell basis did not differ based on CXCR5 expression or HIV infection status ([Figure S1B](#SD1){ref-type="supplementary-material"}). Further, to determine whether CXCR5^+^ CD8^+^ T cells had a differential ability to kill targets compared to CXCR5^−^ CD8^+^ T cells, we performed a redirected cell lysis assay (adapted from [@R29]) measuring induction of active caspase-3 using as effector cells CXCR5^+^ and CXCR5^−^ CD8^+^ T cells isolated from HIV-infected tonsils ([Figure 2D](#F2){ref-type="fig"}). While CD8^+^ T cells from control HIV^+^ PBMCs demonstrated a strong induction of active caspase-3, tonsillar CXCR5^+^ CD8^+^ T cells had very little killing ability in comparison. Moreover, contrary to recent reports ([@R48]), we did not find that CXCR5^+^ CD8^+^ T cells exhibited stronger cytolytic activity than CXCR5^−^ CD8^+^ T cells. Similar to memory CD8^+^ T cells, CXCR5^+^ CD8^+^ T cells displayed dissociated perforin and gzmB co-expression patterns ([Figure 2E](#F2){ref-type="fig"}). Unbiased tSNE analysis showed a similar dissociation trend between perforin and gzmB co-expression ([Figure 2F](#F2){ref-type="fig"}). To confirm whether cytolytic molecule expression patterns in CXCR5^+^ CD8^+^ T cells matched those physically located in B cell follicles, we performed multispectral confocal imaging analysis. CD8^+^ T cells within B cell follicles of HIV^−^ individuals rarely expressed perforin and gzmB ([Figure S1C](#SD1){ref-type="supplementary-material"}). In HIV-infected LNs, irrespective of treatment status, a higher frequency of follicular CD8^+^ T cells expressed perforin or gzmB ([Figures 2G](#F2){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}), but only a small fraction co-expressed both proteins ([Figure S1D](#SD1){ref-type="supplementary-material"}). In contrast to the inverse association between the frequency of LN CXCR5^+^ CD8^+^ T cells and viral load ([Figure 2B](#F2){ref-type="fig"}), we found no association between the frequency of perforin-expressing LN CXCR5^+^ CD8^+^ T cells and viral load ([Figure 2H](#F2){ref-type="fig"}). Together, these data suggest that while follicular CXCR5^+^ CD8^+^ T cells may be a component of viral control, cytolytic properties are unlikely to be the mechanism by which follicular CD8^+^ T cells impact peripheral viremia.

Dissociation between Cytolytic CD8^+^ T Cells and T-Box-Binding Transcription Factors in LNs {#S5}
--------------------------------------------------------------------------------------------

We next addressed the potential mechanisms underlying the differential cytolytic properties of LNs and peripheral blood CD8^+^ T cells. The transcription factors T-bet and eomesodermin (eomes) regulate effector differentiation and cytolytic function in peripheral blood CD8^+^ T cells ([@R14]; [@R26]; [@R45]; [@R50]). High levels of T-bet expression have been associated with cytolytic function in human CD8^+^ T cells ([@R9]; [@R22]). We found that while T-bet^high^ cells were readily detectable in peripheral blood in all subjects tested regardless of HIV infection status, T-bet^high^ CD8^+^ T cells were rare in LNs (p \< 0.001; [Figures 3A](#F3){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}). When found, \~60% of T-bet^high^ cells in the LN expressed perforin, substantially lower than in matched peripheral blood ([Figure S2G](#SD1){ref-type="supplementary-material"}). Because we rarely found T-bet^high^ CD8^+^ T cells in LNs, we focused the remainder of our analysis on characterizing all T-bet^+^ cells rather than separating low versus high expression. As expected, a large proportion of perforin^+^ CD8^+^ T cells in blood co-expressed T-bet, but this association was lost in LN CD8^+^ T cells, especially for HIV^+^ subjects ([Figures 3A](#F3){ref-type="fig"}, [S2A, and S2B](#SD1){ref-type="supplementary-material"}), where perforin^+^ CD8^+^ T cells were less likely to express T-bet. Eomes was expressed in \~40% of blood and LN memory CD8^+^ T cells regardless of infection or treatment status ([Figure S2A](#SD1){ref-type="supplementary-material"}) and was not clearly associated with perforin expression in either blood or LN CD8^+^ T cells ([Figure S2C](#SD1){ref-type="supplementary-material"}). Similarly, few T-bet^+^ CD8^+^ T cells in LNs expressed gzmB compared to blood ([Figures S2D and S2E](#SD1){ref-type="supplementary-material"}). We found no clear association between gzmB expression and eomes in LN or peripheral blood CD8^+^ T cells ([Figures S2D--S2F](#SD1){ref-type="supplementary-material"}). Finally, most perforin/gzmB^+^ PBMC CD8^+^ T cells co-expressed T-bet ([Figure 3B](#F3){ref-type="fig"}), but this association was again absent for LN perforin/gzmB^+^ CD8^+^ T cells ([Figure 3B](#F3){ref-type="fig"}). We further assessed T-bet expression in CXCR5^+^ CD8^+^ T cells. Memory CXCR5^+^ and CXCR5^−^ CD8^+^ T cells had similarly low expression levels of T-bet independent of HIV treatment status ([Figure 3C](#F3){ref-type="fig"}). Together, these data indicate that perforin-expressing memory CD8^+^ T cells in LNs are transcriptionally and functionally distinct from peripheral blood CD8^+^ T cells, especially in HIV-infected LNs.

LN HIV-Specific CD8^+^ T Cells Express Low Levels of Cytolytic Molecules and T-bet {#S6}
----------------------------------------------------------------------------------

Most studies to date have characterized bulk or memory CD8^+^ T cell populations in HIV-infected LNs. However, except for interferon-γ (IFN-γ) ELISpot analysis ([@R3]) and major histocompatibility complex (MHC) class I tetramer quantification ([@R12]), the functional and phenotypic properties of HIV-specific CD8^+^ T cells in LNs remain largely undefined. To address this knowledge gap, we screened for immunodominant HLA-A\*0201-, HLA-A\*2402-, and HLA-B\*0702-restricted HIV-specific CD8^+^ T cell responses in LNs using MHC class I tetramers. Eight paired HIV MHC class I tetramer responses were identified in both HIV-infected LNs and blood from five donors. We found that the frequencies of HIV-specific CD8^+^ T cells were largely similar between blood and LNs ([Figure 4A](#F4){ref-type="fig"}). Overlapping HIV Gag and Env peptide stimulations confirmed that the frequency of IFN-γ^+^ and/or tumor necrosis factor (TNF)^+^ HIV-specific CD8^+^ T cell responses was comparable between blood and LN irrespective of ART status ([Figure S3A](#SD1){ref-type="supplementary-material"}). The memory phenotype of LN HIV-specific CD8^+^ T cells was largely similar to blood, with the exception that effector memory HIV-specific CD8^+^ T cells were more common in blood compared to LN ([Figure 4B](#F4){ref-type="fig"}). Importantly, LN HIV-specific CD8^+^ T cells expressed significantly lower levels of gzmB and perforin compared to peripheral blood ([Figure 4C](#F4){ref-type="fig"}). Perforin frequencies ([Figure S3B](#SD1){ref-type="supplementary-material"}) and median fluorescence intensity (MFI) values ([Figure S3C](#SD1){ref-type="supplementary-material"}) in HIV-specific cytokine-producing CD8^+^ T cells were similar between chronically infected and ART-treated HIV^+^ subjects in both blood and LNs. However, similar to the HIV-tetramer^+^ CD8^+^ T cells, blood HIV-specific CD8^+^ T cells producing IFN-γ and/or TNF demonstrated increased frequency ([Figure S3B](#SD1){ref-type="supplementary-material"}) and MFI ([Figure S3C](#SD1){ref-type="supplementary-material"}) for perforin compared to LN HIV-specific CD8^+^ T cells. Perforin and gzmB expression was almost perfectly correlated in blood HIV-specific CD8^+^ T cells but completely dissociated in LNs ([Figure 4D](#F4){ref-type="fig"}).

We have previously shown that increased effector HIV-specific CD8^+^ T cell functions in peripheral blood are closely related to high expression levels of T-bet and intermediate levels of eomes (T-bet^high^eomes^dim^) ([@R9]). In blood, we found that perforin^+^ HIV-specific CD8^+^ T cells were primarily T-bet^high^eomes^dim^, while perforin^+^ HIV-specific CD8^+^ T cells in LN were instead T-bet^dim^eomes^hi^ ([Figure 4E](#F4){ref-type="fig"}). This latter profile has been associated with exhaustion ([@R9]). As predicted, the frequency of perforin^+^ HIV-tetramer^+^ CD8^+^ T cells in blood was directly associated with a T-bet^high^eomes^dim^ phenotype ([Figure 4E](#F4){ref-type="fig"}), but no association was found between perforin expression and the T-bet^hi^eomes^dim^ profile in LN HIV-specific CD8^+^ T cells ([Figure 4E](#F4){ref-type="fig"}).

Finally, we addressed whether CXCR5^+^ HIV-specific CD8^+^ T cells express cytolytic molecules. Previous immunohistochemistry studies have demonstrated that LN HIV-specific CD8^+^ T cells are primarily compartmentalized to the T cell zone ([@R12], [@R13]). In accordance with these reports, we found that most LN HIV-tetramer^+^ ([Figure 4F](#F4){ref-type="fig"}) and cytokine producing HIV-specific CD8^+^ T cells were CXCR5^−^ ([Figure S3D](#SD1){ref-type="supplementary-material"}) regardless of treatment status. We found no difference in the frequency of perforin expression between CXCR5^+^ and CXCR5^−^ HIV-tetramer^+^ CD8^+^ T cells ([Figure 4F](#F4){ref-type="fig"}). Perforin expression was also indistinguishable between chronically infected and ART-treated subjects for CXCR5^+^ HIV Gag/Env-specific CD8^+^ T cells ([Figure S3E](#SD1){ref-type="supplementary-material"}). Together, these data indicate that LN HIV-specific CD8^+^ T cells, regardless of their follicular localization, do not bear the characteristics of peripheral blood cytolytic CD8^+^ T cells.

Activation Does Not Fully Restore the Cytolytic Properties of LN HIV-Specific CD8^+^ T Cells {#S7}
--------------------------------------------------------------------------------------------

To determine whether activated LN CD8^+^ T cells have or can acquire cytolytic properties, we examined whether *ex vivo* LN CD8^+^ T cells entering the cell cycle, identified as Ki67^+^ ([@R18]), express perforin or gzmB. Similar to blood, LN CD8^+^ T cells displayed higher levels of Ki67 expression in individuals with chronic HIV infection than in HIV^−^ and ART-treated individuals ([Figure S4A](#SD1){ref-type="supplementary-material"}). Ki67^+^ LN memory CD8^+^ T cells in treated and untreated HIV^+^ individuals co-expressed perforin and/or gzmB more frequently than Ki67^+^ LN memory CD8^+^ T cells in HIV^−^ individuals ([Figure S4B](#SD1){ref-type="supplementary-material"}). However, Ki67^−^ cells in HIV^+^ individuals also maintained higher levels of perforin and gzmB expression than HIV^−^ subjects. Ki67^+^ LN memory CD8^+^ T cells were not more likely to express T-bet compared to Ki67^−^ LN memory CD8^+^ T cells in any subject group, but eomes trended toward higher expression in both Ki67^+^ and Ki67^−^ cells in HIV^+^ individuals compared to HIV^−^ controls ([Figures S4D and S4E](#SD1){ref-type="supplementary-material"}).

We next performed *in vitro* carboxyfluorescein succinimidyl ester (CFSE) assays to determine whether proliferating HIV Gag/Nef-specific LN CD8^+^ T cells acquire cytolytic effector properties. Robust cell division was observed in LN ([Figures 5](#F5){ref-type="fig"} and [S4F](#SD1){ref-type="supplementary-material"}) and peripheral blood ([Figure S5](#SD1){ref-type="supplementary-material"}) CD8^+^ T cells after stimulation with HIV Gag/Nef in most HIV-infected donors and after nonspecific stimulation with staphylococcal enterotoxin B (SEB) in all donors. While SEB readily induced perforin, gzmB, and T-bet expression in dividing LN and peripheral blood CD8^+^ T cells after 1 or 2 cell divisions, dividing HIV-specific CD8^+^ T cells differentially upregulated these proteins. Dividing LN HIV Gag/Nef-specific CD8^+^ T cells upregulated perforin and gzmB ([Figures 5A and 5B](#F5){ref-type="fig"}), but not as rapidly or consistently as the SEB control ([Figure S4G](#SD1){ref-type="supplementary-material"}). The amount of perforin on a per cell basis also remained lower for LN CD8^+^ T cells than peripheral blood CD8^+^ T cells ([Figure S5B](#SD1){ref-type="supplementary-material"}). In contrast, SEB-stimulated LN and peripheral blood CD8^+^ T cells upregulated gzmB similarly ([Figures S4G and S5A](#SD1){ref-type="supplementary-material"}). Finally, unlike SEB-stimulated LN CD8^+^ T cells, LN HIV-specific CD8^+^ T cells did not strongly upregulate T-bet ([Figure 5C](#F5){ref-type="fig"}). Together, these results indicate that LN CD8^+^ T cells can gain some aspects of cytolytic function after activation but do not under these conditions acquire the cytolytic properties characteristic of circulating effector CD8^+^ T cells.

Activated LN CD8^+^ T Cells Acquire LN Egress/Tissue Homing Properties but Do Not Acquire LN Follicular Homing Markers {#S8}
----------------------------------------------------------------------------------------------------------------------

Induction of effector function in LN CD8^+^ T cells is associated with upregulation of LN egress and tissue homing proteins ([@R15]; [@R36]; [@R59]; [@R64]). We therefore examined how activated LN CD8^+^ T cells modulate expression of CXCR3, which regulates tissue trafficking ([@R8]; [@R55]), and CD69, which prevents tissue egress via interactions with S1PR ([@R36]). Dividing LN CD8^+^ T cells upregulated CXCR3 within 1 or 2 cell divisions after stimulation with HIV peptides or SEB ([Figures 5D](#F5){ref-type="fig"} and [S4H](#SD1){ref-type="supplementary-material"}). Concomitantly, CD69 was transiently upregulated after \~2 or 3 cell divisions ([Figures 5E](#F5){ref-type="fig"} and [S4H](#SD1){ref-type="supplementary-material"}) and then lost. Finally, we examined whether activated LN CD8^+^ T cells modulate expression of CXCR5. No consistent patterns of CXCR5 upregulation were detected for LN CD8^+^ T cells dividing in response to either HIV peptides or SEB ([Figure S4I](#SD1){ref-type="supplementary-material"}). Recent studies have demonstrated that transforming growth factor β (TGF-β) could selectively induce CXCR5 expression on rhesus macaque LN CD8^+^ T cells ([@R43]). We therefore assessed whether human tonsil CD8^+^ T cells similarly upregulated CXCR5 in response to TGF-β and/or interleukin-12 (IL-12). We did not find that these two cytokines, either alone or in combination, selectively induced CXCR5 expression on dividing cells, but they did each appear to maintain CXCR5 expression on CD8^+^ T cells compared to cells dividing in the absence of these cytokines ([Figure S4J](#SD1){ref-type="supplementary-material"}). Together, these results suggest that HIV-specific CD8^+^ T cells activated *in situ* would be prompted to leave the LN rather than traffic to LN follicles.

DISCUSSION {#S9}
==========

The sequestration of CD4^+^ Tfh cells into B cell follicles during chronic infection represents one mechanism by which CD8^+^ T cells are unable to eliminate HIV-infected CD4^+^ T cell reservoirs ([@R33]; [@R46]; [@R47]). Here, we show that CD8^+^ T cells from human LNs do not possess attributes associated with peripheral cytolytic CD8^+^ T cell function. In HIV infection, LN HIV-specific CD8^+^ T cells acquire some hallmarks of cytolytic function but retain characteristics that likely limit *in vivo* cytolytic activity, including low perforin expression, reduced cytolytic protein co-expression, alternate transcriptional regulation of effector function, and activation-induced tissue trafficking patterns.

Studies of HIV immunopathogenesis have associated CD8^+^ T cell functionality ([@R2]; [@R6]), specificity ([@R19]; [@R38]), proliferative capacity ([@R37]; [@R39], [@R41]), memory phenotype ([@R1]; [@R2]; [@R25]), and cytolytic potential ([@R21]; [@R39], [@R40]; [@R54]) as correlates of protection from disease progression. However, it is unclear whether these peripheral blood CD8^+^ T cell correlates apply to HIV-infected LN. In line with previous studies ([@R3]; [@R12]; [@R44]), we did not find substantial differences in the frequency of HIV-specific CD8^+^ T cells between LNs and peripheral blood. However, profound qualitative differences were apparent between these compartments. While LN HIV-specific CD8^+^ T cells could individually express perforin, gzmB, and/or degranulate (data not shown) in response to stimulation, only a fraction displayed all three attributes, which are required in unison for cytolytic activity. Limited cytolytic potential is further compounded by restricted follicular access, as only a portion of LN memory and HIV-specific CD8^+^ T cells express CXCR5. In concordance with this, we found that CD8^+^ T cells from lymphoid tissue, regardless of whether they express CXCR5, were very limited in their ability to kill target cells. Accordingly, strategies designed to eliminate viral reservoirs in lymphoid tissue by re-invigorating HIV-specific CD8^+^ T cell cytolytic activity in ART-treated individuals must contend with additional factors beyond the follicular localization of HIV-infected CD4^+^ T cells.

The transcription factors T-bet ([@R60]; [@R61]) and eomes ([@R14]; [@R45]; [@R49]) have been highly associated with cytolytic function in CD8^+^ T cells. The finding that T-bet was not associated with cytolytic molecule expression in LN CD8^+^ T cells was unexpected, especially because peripheral blood CD8^+^ T cells from the same individuals demonstrated coordinate expression of T-bet and perforin. Moreover, T-bet expression was substantially lower in LN CD8^+^ T cells than in peripheral blood CD8^+^ T cells and did not associate with effector-like memory CD8^+^ T cells. Although eomes induces effector CD8^+^ T cell differentiation in mice ([@R50]), we found no association with cytolytic protein expression in human blood or LNs. However, we did find more eomes-expressing CD8^+^ T cells in HIV-infected compared to uninfected LNs. These data suggest that transcriptional control of CD8^+^ T cell cytolytic function is regulated differently in LNs and blood or perhaps that temporal regulation prevents the acquisition of cytolytic function in LNs. In line with this, activated LN CD8^+^ T cells were able to express perforin, gzmB, and T-bet after cell division, but this gain of function was coupled with a concomitant modulation of trafficking markers to promote LN egress. These findings are consistent with mouse models ([@R64]) and predictable based on canonical T cell responses to disease ([@R35]). Together, these findings indicate that we have yet to identify all of the mechanisms that control cytolytic protein expression and effector function in lymphoid tissue.

Recent murine data have demonstrated that follicular CXCR5^+^ CD8^+^ T cells are a central component of antiviral immunity ([@R20]; [@R24]; [@R32]). However, it is unclear whether CXCR5^+^ CD8^+^ T cells in these studies represent bona fide cytolytic CD8^+^ T cells. Here, we applied an extensive assessment of cytolytic killing through measurement of the simultaneous expression of perforin and gzmB, killing ability, and the underlying transcriptional programming necessary for cytolytic effector activity directly *ex vivo* from human lymphoid tissue. In agreement with mouse studies, our results indeed suggest that CXCR5^+^ CD8^+^ T cells in lymphoid tissue play a role in the immune response against HIV. However, we also found that the strong inverse correlation between peripheral viremia and the frequency of CXCR5^+^ CD8^+^ T cells in lymphoid tissue is not dependent on cytolytic machinery. This finding links conceptually with previous studies implicating non-cytolytic mechanisms as key determinants of immune protection against HIV and SIV ([@R7]; [@R30]; [@R65]).

In summary, we have shown that CD8^+^ T cells with cytolytic potential are relatively absent from human LNs. This finding suggests the existence of a biological mechanism that limits CD8^+^ T cell-mediated immunopathology and enables antigen presentation in a protected environment to facilitate the uninterrupted development of adaptive immune responses. However, the presence of an anatomically defined niche with immune privileges also provides a safe haven for various intracellular pathogens such as HIV. Importantly, these concepts also extend to mucosal tissues, as similar observations of limited cytolytic ability, low perforin expression, and low T-bet expression by mucosal tissue CD8^+^ T cells are apparent in both uninfected and chronically HIV-infected subjects ([@R29]; [@R52]; [@R57]). Novel therapeutic strategies will therefore be required to counteract this natural lack of immune surveillance in the effort to purge and eradicate HIV reservoirs from both lymphoid and nonlymphoid tissues.

EXPERIMENTAL PROCEDURES {#S10}
=======================

Study Groups {#S11}
------------

Peripheral blood collection and/or LN biopsies were performed in 80 individuals classified as HIV^−^ (n = 40), HIV^+^ chronic untreated (n = 25), or HIV^+^ on ART (n = 15). Subject grouping, age, sex, sample collection, and clinical parameters are summarized in [Table 1](#T1){ref-type="table"}. All enrolled participants gave written informed consent as per protocols approved by the INER-CIENI ethics committee and the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), the institutional review boards of the University of Pennsylvania and Case Western Reserve University, or the University General Hospital of Heraklion, Crete, Greece. Sample sizes were based on the availability of biological samples rather than a prespecified effect size. Exclusion criteria for samples were solely based on cell viability \>70%.

Flow Cytometry {#S12}
--------------

PBMC and LNMC stimulations were performed from cryopreserved material as described previously ([@R21]; [@R34]). Cells were incubated at a concentration of 1--2 × 10^6^ cells/mL in complete medium (1 mL per condition) in the presence of costimulatory antibodies (3 µL/mL BD FastImmune α-CD28/CD49d, clones L293 and L25, BD Biosciences) and α-CD107a PE-Cy5 (clone H4A3, eBioscience) to measure degranulation for 6 hr total at 37°C in a 5% CO~2~ atmosphere with peptide pools representing HIV-1 Gag or Env gp120 (2 µg/mL, clade B, NIH AIDS Reagent Program) or epitopes from cytomegalovirus, Epstein-Barr virus, and influenza virus (1 µg/mL each, NIH AIDS Reagent Program; [@R28]; [@R42]; [@R63]). As a positive control, cells were stimulated with 1 µg/mL SEB (Sigma). After 1 hr, cultures were supplemented with 1 µg/mL brefeldin A (Sigma) and 0.7 µL/mL BD GolgiStop (BD Biosciences).

Proliferation assays were performed using PBMCs and LNMCs labeled with CellTrace CFSE (Molecular Probes, Invitrogen). Cells were stimulated with peptide pools spanning HIV-1 Gag and Nef (1 µg/mL each, clade B consensus, NIH AIDS Reagent Program, Division of AIDS \[DAIDS\], National Institute of Allergy and Infectious Diseases \[NIAID\], NIH) or 1 µg/ml SEB (Sigma) for 5 days in the presence of recombinant human IL-2 (100 U/mL) and plate-bound α-CD28/CD49d (BD Biosciences).

All flow cytometry immunostaining was performed as described previously ([@R21]; [@R34]). The antibodies and MHC tetramers used are described in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}. Briefly, cells were washed in PBS and, in some cases, incubated with α-CCR7 at 37°C. Cells were labeled with the amine reactive dye LIVE/DEAD Fixable Aqua (Molecular Probes, Invitrogen) prior to incubation with antibodies against surface proteins. Intracellular proteins and cytokines were labeled after subsequent fixation/permeabilization with BD Cytofix/Cytoperm (BD Biosciences). For tetramer analyses, cells were incubated with tetramers for 10 min before pre-stain. All MHC class I tetramers were produced as described previously ([@R51]). Cells were fixed in paraformaldehyde before analysis.

Cytometric Analyses {#S13}
-------------------

For all flow cytometric assays, at least 500,000 events were acquired using a modified LSR-II equipped with FACSDIVA software (BD Biosciences). Data were analyzed with FlowJo software (version 9.8.5, Tree Star). The following gating scheme was used to identify CD8^+^ T cells of interest: a time gate to ensure sample flow rate was consistent, singlets, lymphocytes, viable (LIVE/DEAD Aqua^−^), CD14^−^, CD16^−^, CD19^−^, CD3^+^, CD4^−^, CD8^+^. Cell divisions within the proliferation experiments were determined automatically using the FlowJo cell proliferation platform, assuming the default maximal cell division number of 8. Cell division "bins" were then applied to the CFSE dilution of each individual marker of interest in order to define modulation of specific markers with respect to cell division history.

Cell ACCENSE (automatic classification of cellular expression by nonlinear stochastic embedding) analyses were performed to visualize phenotypic relationships within multivariate data obtained from resting cells from 14 individuals (4--5 from each group). This program combines nonlinear dimensionality reduction with density-based partitioning, outputting unbiased protein expression data from all measured parameters as a two-dimensional plot ([@R58]; [@R62]). PBMC and LNMC memory CD8^+^ T cell or LNMC CXCR5^+^/CXCR5^−^ memory CD8^+^ T cell data were exported from FlowJo as FCS files. Cell ACCENSE was used to perform a Barnes-Hut-SNE dimensional reduction analysis on a total of 800,000 downsampled events to generate two-dimensional tSNE plots.

Imaging Analysis {#S14}
----------------

Paraffin-embedded sections (6--10 µm) were deparaffinized, and antigen retrieval was performed using a decloaking chamber (125°C, 30 s, Biocare Medical) with Borg Decloaker buffer (Biocare Medical). Tissues were blocked (0.1 M Tris, 0.3% Triton X-100, 1% BSA) for 1 hr at room temperature (RT), stained with titrated amounts of nonconjugated antibodies (α-granzyme B, α-CD8) overnight at 4°C, washed with PBS (3 × 20 minutes), and stained with the appropriate secondary antibodies for 2 hr at RT. After a second blocking step with a 1:1 mixture of normal mouse serum (1 hr at RT), tissues were stained with titrated amounts of directly conjugated antibodies (α-CD20, α-perforin). JoJo staining was performed after a final wash step, and the slides were mounted with Fluoromount G (SouthernBiotech). Images were collected on a Leica SP8 confocal microscope using a 20× 0.75 numerical aperture (NA) or 40× 1.30 NA objective with a 1.5× optical zoom at a density of 1,024 × 1,024 pixels. Additional images were captured using a 63× 1.40 NA objective. Fluorophore spillover was corrected by imaging single-stained tissues and creating a compensation matrix via the Leica LAS-AF Channel Dye Separation module (Leica Microsystems). Compensated images were analyzed with Imaris software (Bitplane Scientific).

Statistical Analyses {#S15}
--------------------

Statistical analyses were performed with Prism software (version 5.0a, GraphPad). Non-parametric tests were used to determine significance between groups using the Mann-Whitney two-tailed test (for two groups), the Kruskal-Wallis test with Dunn's post-test (for three or more groups), or the Wilcoxon matched-pairs two-tailed test (for paired samples) (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001).

Supplementary Material {#SM}
======================

[SUPPLEMENTAL INFORMATION](#SD1){ref-type="supplementary-material"}

[Supplemental Information](#SD1){ref-type="supplementary-material"} includes Supplemental Experimental Procedures and five figures and can be found with this article online at <https://doi.org/10.1016/j.celrep.2017.11.075>.
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![HIV Infection Induces Accumulation of Effector Memory CD8^+^ T Cells with Low Levels of Perforin Expression in LNs\
(A) Representative flow plots (left) showing CD3^+^ CD8^+^ T cells in PBMCs (top) and LNMCs (bottom) from a chronically infected HIV^+^ individual, and a comparison of memory subsets (right) in PBMCs versus LNMCs.\
(B) Representative flow plots (left) showing memory CD8^+^ T cell expression of perforin in PBMCs (top row) versus LNMCs (bottom row) from an HIV^−^ individual versus a chronically infected HIV^+^ individual. Perforin frequency and MFI in memory CD8^+^ T cells in PBMCs versus LNMCs is shown on the right for HIV^−^, chronic HIV^+^, and ART-treated HIV^+^ individuals.\
(C) Representative flow plots (left) showing perforin versus gzmB expression in PBMCs (top) versus LNMCs (bottom) from an ART-treated HIV^+^ individual, and frequency of perforin co-expression in gzmB^+^ memory CD8^+^ T cells (right) in PBMCs versus LNMCs.\
(D) Cell ACCENSE tSNE plots of perforin and gzmB expression in memory CD8^+^ T cells comparing PBMCs and LNMCs from ART-treated HIV^+^ individuals (based on n = 4/group). The highlighted area in lower right of each tSNE plot represents cytolytic effector CD8^+^ T cells.\
The statistical tests used were the Kruskal-Wallis test with Dunn's post-test (for between-subject groups within a tissue compartment), the Mann-Whitney test (for within a subject group between tissue compartments), and the Wilcoxon matched-pairs two-tailed test (for paired samples). \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Blue circle, open blue circle, HIV^−^; black square, open black square, HIV^+^ therapy naive; red triangle, open red triangle, HIV^+^ on ART. Ranges shown on plots represent mean ± SEM. In all figures, closed symbols represent PBMCs and open symbols represent LNMCs. Memory subsets were determined by CD27 and CD45RO expression patterns.](nihms927648f1){#F1}

![CXCR5^+^ CD8^+^ T Cells Are Associated with Control of HIV Independent of Perforin Expression in LNs\
(A) Representative flow plot (left) showing memory CD8^+^ T cell expression of CXCR5 in LNMCs from a chronically infected HIV^+^ individual, and frequency of LN CXCR5^+^ memory CD8^+^ T cells (right) in HIV^−^, chronic HIV^+^, and ART-treated HIV^+^ individuals.\
(B) The frequency of CXCR5^+^ memory CD8^+^ T cells in LNMCs is inversely associated with HIV plasma viral load. Statistical significance was determined using Spearman's test. Data shown were obtained from untreated HIV^+^ individuals with chronic infection.\
(C) Perforin frequency in CXCR5^+^ and CXCR5^−^ memory CD8^+^ T cells in LNMCs.\
(D) Redirected killing assay measuring the ability of tonsillar CXCR5^+^ and CXCR5^−^ CD8^+^ T cells isolated from n = 4 donors to kill anti-CD3 coated P815 target cells using activate caspase-3 as a readout.\
(E) Frequency of gzmB co-expression in perforin^+^ CXCR5^+^ memory CD8^+^ T cells in LNMCs.\
(F) Cell ACCENSE tSNE plots of perforin and gzmB expression in CXCR5^+^ memory CD8^+^ T cells in LNMCs from ART-treated HIV^+^ individuals (tSNE based on n = 4).\
(G) IHC staining of paraffin-embedded tissue sections showing CD8^+^ T cells in B cell follicles. Top row: low-magnification view of a representative B cell follicle from a chronically infected HIV^+^ individual (scale bar, 100 µm). Boxes highlight areas for 10× zoom in bottom row (scale bar, 10 µm). Purple, CD19; cyan, CD8; red, perforin; green, gzmB.\
(H) The frequency of perforin-expressing CXCR5^+^ CD8^+^ T cells in LNMCs is not associated with HIV plasma viral load. Statistical significance was determined using Spearman's test. Data shown were obtained from untreated HIV^+^ individuals with chronic infection.\
Statistical significance between subject groups was determined using the Kruskal-Wallis test with Dunn's post-test. Statistical significance within a subject group between tissue compartments was determined using the Mann-Whitney two-tailed test. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Open blue circle, HIV^−^; open black square, HIV^+^ therapy naive; open red triangle, HIV^+^ on ART. Ranges shown on plots represent mean ± SEM.](nihms927648f2){#F2}

![CD8^+^ T Cells Exhibit Dissociation between Transcriptional Drivers of Cytolytic Function and Expression of Cytolytic Proteins in LNs\
(A) Representative flow plots (left) showing memory CD8^+^ T cell expression of T-bet and perforin in PBMCs and LNMCs from an ART-treated HIV^+^ individual, and frequency of T-bet^high^ memory CD8^+^ T cells (right) in PBMCs and LNMCs. T-bet gating shown is the sum of the upper gates in the representative flow plots.\
(B) T-bet frequency in memory CD8^+^ T cells expressing perforin and/or gzmB in PBMCs and LNMCs.\
(C) Representative flow plots (left) showing memory CD8^+^ T cell expression of T-bet and CXCR5 in LNMCs from HIV− and HIV+ chronic, and T-bet frequency in CXCR5^+^ and CXCR5^−^ CD8^+^ T cells (right) in LNMCs.\
Statistical significance between subject groups within a tissue compartment was determined using the Kruskal-Wallis test with Dunn's post-test. Statistical significance within a subject group between tissue compartments was determined using the Mann-Whitney two-tailed test. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Blue circle, open blue circle, HIV^−^; black square, open black square, HIV^+^ therapy-naive; red triangle, open red triangle, HIV^+^ on ART. Ranges shown on plots represent mean ± SEM.](nihms927648f3){#F3}

![HIV-Specific CD8^+^ T Cells Are Poorly Cytolytic and Express Low Levels of T-Bet and CXCR5 in LNs\
(A) Flow plots (left) showing FLGKIWPSHK (FK10)/HLA-A\*0201 and ILKEPVHGV (IV9)/HLA-A\*0201 tetramer stains of PBMCs and LNMCs from the same subject, and frequency of matched HIV-tetramer^+^ CD8^+^ T cell responses (right) in PBMCs and LNMCs.\
(B) Compartmentalization of HIV-tetramer^+^ CD8^+^ T cell responses within different memory subsets: central memory (CM; CCR7^+^ CD27^+^ CD45RO^+^), transitional memory (TM; CCR7^−^ CD27^+^ CD45RO^+^), effector memory (EM; CCR7^−^ CD27^−^ CD45RO^+^), and terminally differentiated (TD; CCR7^−^ CD27^−^ CD45RO^−^).\
(C) Flow cytometry plots (left) showing gzmB expression in HIV-tetramer^+^ CD8^+^ T cells in PBMCs and LNMCs from the same subject, and frequency of perforin and gzmB expression for all HIV-tetramer^+^ CD8^+^ T cells (right) in PBMCs and LNMCs.\
(D) Frequency of perforin and gzmB co-expression in matched HIV-tetramer^+^ CD8^+^ T cells (left) in PBMCs (blue) and LNMCs (red), and correlation between perforin^+^ and gzmB^+^ HIV-tetramer^+^ CD8^+^ T cells (right) in PBMCs (blue) and LNMCs (red).\
(E) Frequency of perforin^+^ HIV-tetramer^+^ CD8^+^ T cells within the T-bet^high^eomes^dim^ population (left) in PBMCs (blue) and LNMCs (red), and correlation between perforin^+^ and HIV-tetramer^+^ CD8^+^ T cells (right) in PBMCs (blue) and LNMCs (red).\
(F) Flow plots (left) showing HIV-tetramer^+^ CD8^+^ T cell expression of CXCR5 and perforin for two distinct specificities in LNMCs from the same subject, frequency of CXCR5^+^ versus CXCR5^−^ HIV-tetramer^+^ CD8^+^T cells (middle) in LNMCs, and perforin expression in CXCR5^+^ and CXCR5^−^ HIV-tetramer^+^ CD8^+^ T cells (right) in LNMCs. Flow plots are representative of chronically infected HIV^+^ individuals. Statistical significance within a subject group between tissue compartments was determined using the Mann-Whitney two-tailed test. Statistical significance for correlations was determined using Spearman's test. Ranges shown on plots represent median and interquartile range (IQR).](nihms927648f4){#F4}

![Proliferating CD8^+^ T Cells Do Not Fully Acquire Cytolytic Properties and Express Marker Patterns Associated with Tissue Egress in LNs\
(A--E) Assessment of perforin (A), gzmB (B), T-bet (C), CXCR3 (D), and CD69 (E) expression in CFSE-labeled total CD8^+^ T cells in LNMCs after 5 days of stimulation with HIV clade B consensus Gag and Nef peptides (n = 5 HIV^−^, HIV^+^; n = 4 HIV^+^ ART). Flow plots (left) show representative data from an ART-treated HIV^+^ individual, and graphs (right) show protein expression frequency versus cell division (0--8 on the x axis). The gating strategy is shown in [Figure S4F](#SD1){ref-type="supplementary-material"}. D0 refers to prestimulation protein expression levels. Open blue circle, HIV^−^; open black square, HIV^+^ therapy naive; open red triangle, HIV^+^ on ART. Ranges shown on plots represent mean ± SEM.](nihms927648f5){#F5}

###### 

Clinical Characteristics of Subjects in Designated Groups

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Status         No. of\    Time on ART\                              Viral load RNA (Copies/mL)[a](#TFN2){ref-type="table-fn"}   Log Viral Load[a](#TFN2){ref-type="table-fn"}   CD4 Count (Cells/µL)[a](#TFN2){ref-type="table-fn"}   Sex (M/F)   Age (Years)[a](#TFN2){ref-type="table-fn"}   PBMCs/LNMCs\   Sample Origin
                 Subjects   (Months)[a](#TFN2){ref-type="table-fn"}                                                                                                                                                                                                                              (Matched)      
  -------------- ---------- ----------------------------------------- ----------------------------------------------------------- ----------------------------------------------- ----------------------------------------------------- ----------- -------------------------------------------- -------------- ----------------------------------------------------------
  HIV^−^         41         N/A                                       N/A                                                         N/A                                             1,319 (1,267--1,371), 2                               15/18       38 (17--86), 33                              23/20 (2)      Ohio (16), Mexico (8), Pennsylvania (15), and Greece (2)

  Chronic        27         N/A                                       56,009 (1,439--1,387,603), 27                               4.75 (3.16--6.14), 27                           523 (142--1,130), 27                                  25/2        31 (20--62), 27                              22/25 (20)     Mexico (27)

  Chronic, ART   17         7 (1--108), 15                            93 (20--7,103), 16                                          1.96 (1.6--3.9), 15                             301 (199--834), 17                                    15/2        32 (22--51), 16                              16/16 (15)     Mexico (15) and Pennsylvania (2)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N/A, not applicable.

Data are presented as median (range), number of subjects.

###### Highlights

-   CD8^+^ T cells in quiescent lymphoid tissues do not express markers of cytotoxicity

-   Lymphoid tissue HIV-specific CD8^+^ T cells do not possess full cytolytic markers

-   Noncytolytic CXCR5^+^ CD8^+^ T cells in lymphoid tissue associate with viral control
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